Preeclampsia Prevention and Management: Aspirin Prophylaxis Evidence

Magnesium Sulfate for Seizure Prophylaxis

Magnesium sulfate is the gold standard for eclampsia prophylaxis in severe preeclampsia. The Magpie trial (10,141 women) demonstrated a 58% reduction in eclampsia risk (RR 0.42, 95% CI 0.29-0.60)[5]. Standard protocol: 4-6 g IV loading dose over 20-30 minutes followed by 1-2 g/hour continuous infusion for 24-48 hours after delivery or last seizure. Monitor patellar reflexes, urine output (target above 30 mL/hour), and respiratory rate. Therapeutic range is 4.8-8.4 mg/dL; toxicity manifests as loss of deep tendon reflexes (above 10 mg/dL) and respiratory depression (above 12 mg/dL). Calcium gluconate 1g IV is the antidote for magnesium toxicity.

Delivery Timing and Postpartum Surveillance

Delivery is the definitive treatment for preeclampsia. Current recommendations: deliver at 37 weeks for preeclampsia without severe features, and at 34 weeks (or earlier if maternal or fetal status deteriorates) for preeclampsia with severe features[6]. Postpartum preeclampsia can develop up to 6 weeks after delivery, and patients should be counseled on warning signs (severe headache, visual changes, epigastric pain, new hypertension). Women with a history of preeclampsia have a 2-4 fold increased lifetime cardiovascular disease risk, warranting long-term blood pressure management[7] and should receive long-term cardiovascular risk assessment and modification.

The Implementation Problem

The evidence for aspirin prophylaxis is strong and the intervention is simple and inexpensive, yet implementation rates remain suboptimal. Risk factors are not systematically assessed at the first prenatal visit in many practices, aspirin is started after the optimal window (particularly when prenatal care begins late), and the dose used in North America may be subtherapeutic relative to the ASPRE protocol that generated the strongest evidence. The highest-yield quality improvement intervention for most obstetric practices is a standardized first-trimester risk assessment protocol that triggers an aspirin prescription before the patient leaves the visit — removing the chance that this simple but high-impact intervention is forgotten or deferred.

Limitations and Unresolved Questions

The ASPRE trial used first-trimester combined screening (maternal factors, uterine artery Doppler, MAP, serum biomarkers) for risk stratification — a protocol that is not universally available, particularly in resource-limited settings where preeclampsia burden is highest. Whether the North American standard dose of aspirin at the lower end of the effective range provides equivalent protection to the ASPRE dose remains a practical uncertainty. Aspirin prophylaxis prevents preterm preeclampsia effectively but has minimal impact on term preeclampsia, which accounts for a substantial proportion of cases. And the pathophysiology of preeclampsia — involving defective placentation, endothelial dysfunction, and systemic inflammation — is incompletely understood, meaning that aspirin addresses only one mechanistic pathway in a complex disease process.

References

1. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
2. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
3. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
4. Aspirin for prevention of preeclampsia: dose-response meta-analysis
5. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial
6. ACOG Practice Bulletin 222: Gestational Hypertension and Preeclampsia
7. Hypertensive disorders of pregnancy and future cardiovascular risk